KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Short term Debt: 2009-2013

Historic Short term Debt for Arbutus Biopharma (ABUS) over the last 2 years, with Dec 2013 value amounting to $1,723.9 billion.

  • Arbutus Biopharma's Short term Debt fell 2.65% to $1,723.9 billion in Q4 2013 from the same period last year, while for Dec 2013 it was $1,723.9 billion, marking a year-over-year decrease of 2.65%. This contributed to the annual value of $1,723.9 billion for FY2013, which is 1.81% down from last year.
  • As of Q4 2013, Arbutus Biopharma's Short term Debt stood at $1,723.9 billion, which was up 100,174,767.56% from $1.7 million recorded in Q3 2013.
  • In the past 5 years, Arbutus Biopharma's Short term Debt ranged from a high of $2,127.2 billion in Q4 2010 and a low of $316,214 during Q4 2009.
  • Over the past 3 years, Arbutus Biopharma's median Short term Debt value was $2.2 million (recorded in 2011), while the average stood at $788.9 billion.
  • Per our database at Business Quant, Arbutus Biopharma's Short term Debt soared by 672,699,326.66% in 2010 and then fell by 20.53% in 2011.
  • Quarterly analysis of 5 years shows Arbutus Biopharma's Short term Debt stood at $316,214 in 2009, then spiked by 672,699,326.66% to $2,127.2 billion in 2010, then dropped by 20.53% to $1,690.5 billion in 2011, then climbed by 4.75% to $1,770.7 billion in 2012, then declined by 2.65% to $1,723.9 billion in 2013.
  • Its Short term Debt stands at $1,723.9 billion for Q4 2013, versus $1.7 million for Q3 2013 and $1.9 million for Q2 2013.